Lunai Bioworks (LNAI) Other Non Operating Income (2013 - 2026)
Lunai Bioworks (LNAI) posted quarterly Other Non Operating Income of -$19966.0 for Q1 2026, down 27830.56% year-over-year from N/an in Q1 2025, and up 99.69% quarter-over-quarter from -$6.4 million in Q4 2025.
Lunai Bioworks (LNAI) Other Non Operating Income (2013 - 2026) Analysis & Trends
Lunai Bioworks' Other Non Operating Income history runs 14 years deep, the most recent figure standing at -$19966.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 27830.56% year-over-year to -$19966.0; the TTM figure through Mar 2026 stood at -$6.3 million (down 387.17% YoY), while the FY2024 annual figure was -$1.4 million, down 139590.78% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$19966.0, up from -$6.4 million in the prior quarter.
- The five-year high for Other Non Operating Income was $418163.0 in Q2 2023, with the low at -$6.4 million in Q4 2025.
- The 5-year median for Other Non Operating Income is -$19966.0 (2026), against an average of -$863780.7.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income sank 4657677.78% in 2022, then surged 99.99% in 2025.
- Lunai Bioworks' Other Non Operating Income stood at -$419182.0 in 2022, then surged by 71.37% to -$120018.0 in 2023, then plunged by 986.03% to -$1.3 million in 2024, then plunged by 388.16% to -$6.4 million in 2025, then jumped by 99.69% to -$19966.0 in 2026.
- Business Quant data shows LNAI's Other Non Operating Income at -$19966.0 in Q1 2026, -$6.4 million in Q4 2025, and $33297.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19,966.00 |
| Dec 31, 2025 | -6.36 Mn |
| Sep 30, 2025 | 33,297.00 |
| Jun 30, 2025 | -72.00 |
| Mar 31, 2025 | 72.00 |
| Jun 30, 2024 | -1.30 Mn |
| Sep 30, 2023 | -120,018.00 |
| Jun 30, 2023 | 418,163.00 |
| Sep 30, 2022 | -419,182.00 |
| Sep 30, 2021 | 9.00 |
| Jun 30, 2021 | -124.00 |
| Mar 31, 2021 | -221.00 |
| Dec 31, 2020 | -32,289.00 |
| Mar 31, 2020 | 5,000.00 |
| Dec 31, 2019 | -137,448.00 |
| Sep 30, 2019 | 286,755.00 |
| Jun 30, 2019 | 11,034.00 |
| Mar 31, 2019 | 164,114.00 |
| Dec 31, 2018 | -169,483.00 |
| Sep 30, 2018 | -31,978.00 |